MUSC HEALTH FLORENCE MEDICAL CENTER
1. Target Overview & Investment Thesis
MUSC HEALTH FLORENCE MEDICAL CENTER is a 187-bed suburban community hospital in FLORENCE, SC with $252.9M in net patient revenue and a -6.9% operating margin. The hospital serves a payer mix of 27.9% Medicare, 8.9% Medicaid, and 63.2% commercial.
Thesis: Undervalued. Our ML models identify $18.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.9% to 0.4% (+736bps).
| Net Revenue HCRIS | $252.9M |
| Current EBITDA COMPUTED | $-17.5M |
| Operating Margin COMPUTED | -6.9% |
| Occupancy HCRIS | 77.0% |
| Revenue / Bed COMPUTED | $1.4M |
| Net-to-Gross HCRIS | 11.4% |
| Distress Probability ML | 41.2% |
2. Market Context & Competitive Position
SC has 85 Medicare-certified hospitals with a median operating margin of 1.3%. The target's margin of -6.9% places it below the state median. Among 30 size-comparable peers (94-374 beds), the median margin is -0.0%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (94-374), prioritizing same-state peers. 30 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| MUSC HEALTH FLORENCE MEDICAL C (Target) | SC | 187 | $252.9M | -6.9% |
| ST. FRANCIS HOSPITAL INC | SC | 327 | $691.4M | 4.9% |
| GRAND STRAND REGIONAL MEDICAL | SC | 336 | $602.2M | 32.8% |
| ANMED HEALTH | SC | 367 | $596.7M | -2.3% |
| SELF REGIONAL HEALTHCARE | SC | 290 | $410.1M | 4.7% |
| ROPER HOSPITAL INC. | SC | 266 | $400.8M | -3.0% |
| PIEDMONT MEDICAL CENTER | SC | 374 | $387.0M | 8.3% |
| BON SECOURS ST. FRANCIS XAVIER | SC | 186 | $304.6M | 12.2% |
| PRISMA HEALTH BAPTIST HOSPITAL | SC | 246 | $277.5M | 0.4% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $18.6M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $5.3M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $5.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $5.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $3.1M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $162K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-17.5M |
| + RCM Uplift | +$18.6M |
| Pro Forma EBITDA | $1.1M |
| Current Margin | -6.9% |
| Pro Forma Margin | 0.4% |
| WC Released (1x) | $9.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-26.9M | $70.7M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-26.9M | $69.0M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-24.2M | $121.7M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-24.2M | $125.6M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-29.6M | $-13.7M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-29.6M | $-24.7M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 30 hospitals with 94-374 beds
- Same-state prioritization (n=31)
- Comp margins: P25=-14.3% / P50=-0.0% / P75=8.3%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.